{
    "clinical_study": {
        "@rank": "102565", 
        "arm_group": [
            {
                "arm_group_label": "P2B001 treatment A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "P2B001 Treatment B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate an oral fixed-dose, once daily product that combines pramipexole\n      and rasagiline for the treatment of early Parkinson's disease.\n\n      Animal studies support the therapeutic advantage of combining low doses of rasagiline and\n      pramipexole and suggest further improvement when both are administered in a sustained\n      fashion. Both rasagiline and pramipexole are well known marketed drugs for Parkinson's\n      disease with a good safety profile. combining the drugs in low doses and controlled release\n      may provide better symptom management than the existing drugs alone or together."
        }, 
        "brief_title": "Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease", 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is male or female \u226535 years of age to \u226475 years of age at the time of\n             enrollment.\n\n          -  Subject has idiopathic Parkinson's disease consistent with the UK Brain Bank\n             Criteria; must have bradykinesia with sequence effect and rest tremor or prominent\n             motor asymmetry.\n\n          -  Subject with disease duration no longer than 3 years and 0 months.\n\n          -  Subject has a Hoehn & Yahr (H&Y) stage score of < 3.\n\n          -  Subject has a MMSE score \u2265 26\n\n        Exclusion Criteria:\n\n          -  Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to\n             drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or\n             degenerative disease).\n\n          -  Subject has a history of psychosis or hallucinations within the previous 12 months.\n\n          -  Subject who is taking anticholinergic drugs.\n\n          -  Subject has previous exposure to levodopa or a dopamine agonist for longer than 4\n             weeks; if previous exposure was less than 4 weeks then it must not be within 2 months\n             prior to the baseline visit.\n\n          -  Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if\n             previous exposure was less than 4 weeks then it must not be within 3 months prior to\n             the baseline visit.\n\n          -  Subject who is taking MAO inhibitors, potent CYP1A2 inhibitors, e,g, Ciprofloxacin,\n             Dextromethorphan or antitussive agent, analgesic agents such as tramadol, meperidine,\n             methadone and propoxyphene, strong 3A4 inducers, e.g., St. John's Wort or\n             cyclobenzaprine (tricyclic muscle relaxant), dopamine antagonists, such as the\n             neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide.\n             Probenecid, cimetidine, ranitidine, diltiazem, verapamil and quinidine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "id_info": {
            "nct_id": "NCT01968460", 
            "org_study_id": "P2B001/001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "P2B001 treatment A", 
                    "P2B001 Treatment B"
                ], 
                "intervention_name": "Pramipexole  / Rasagiline Mesylate once daily", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rasagiline", 
                "Pramipexol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Parkinson's Disease, Rasagiline, Pramipexole", 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "contact": {
                    "email": "thurlow@uchc.edu", 
                    "last_name": "Sheila Thurlow"
                }, 
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "P2B001 Manchester"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "info@indd.org", 
                    "last_name": "Laura Leary"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "P2B001 Site New Haven"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lcarvajal@parkinsonscenter.org", 
                    "last_name": "Lisbeth Carvajal"
                }, 
                "facility": {
                    "address": {
                        "city": "Boca Raton", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "P2B001 Site Boca Raton"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "judys@parkinsonsfl.com", 
                    "last_name": "Judy Seymour"
                }, 
                "facility": {
                    "address": {
                        "city": "Port Charlotte", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "P2B001 Site Port Charlotte"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "P2B001 Site Boston"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "RESEARCHLI@PARKINSONSCENTER.ORG", 
                    "last_name": "Nancy Gardella"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "P2B001 site Commack"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "shannon.martin@mdcok.com", 
                    "last_name": "Shannon Martin"
                }, 
                "facility": {
                    "address": {
                        "city": "Tulsa", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }, 
                    "name": "P2B001 Site Tulsa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "danielle.stanley1@aol.com", 
                    "last_name": "Danielle Stanley"
                }, 
                "facility": {
                    "address": {
                        "city": "Roanoke", 
                        "country": "United States", 
                        "state": "Virginia"
                    }, 
                    "name": "P2B001 Site Roanoke"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease", 
        "overall_contact": {
            "email": "VerfChristopher@PRAIntl.com", 
            "last_name": "Christopher Verf", 
            "phone": "+1 250.483.4597"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline to final visit (week 12) in total UPDRS score (defined as sum of parts I, II and III, scores (0-176).", 
            "measure": "Total UPDRS I, II, III scores", 
            "safety_issue": "Yes", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968460"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in individual UPDRS ADL (part II)", 
                "measure": "UPDRS ADL (part II)", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Change from baseline in individual Clinical Global Impression - Severity", 
                "measure": "CGI-S", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Change from baseline in individual UPDRS motor (part III)", 
                "measure": "UPDRS Motor (part III)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Change from baseline in individual Parkinson's Disease Questionnaire - 39", 
                "measure": "PDQ39", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Pharma Two B Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharma Two B Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}